코로나바이러스감염증-19 (coronavirus disease 2019) 백신과 이상 반응

키워드

참고문헌 (79)

1. Zhu N, "A novel coronavirus from patients with pneumonia in China, 2019", N Engl J Med, 382, pp.727~733 (2020)
2. "Coronavirus disease 2019 (COVID-19): situation report, 51" (2021)[URL]
3. "Clinical management of COVID-19" (2021)[URL]
4. .,
5. "WHO Coronavirus (COVID-19) Dashboard" (2021)[URL]
6. "Draft landscape and tracker of COVID-19 candidate vaccines" (2020)[URL]
7. Polack FP, "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine", N Engl J Med, 383, pp.2603~2615 (2020)
8. Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222)against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", Lancet, 397, pp.99~111 (2021)
9. Sadoff J, "Interim results of a phase 1-2a Trial of Ad26.COV2.S Covid-19 vaccine", N Engl J Med, 384, pp.1824~1835 (2021)
10. Zhu FC, "Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine : a dose-escalation, open-label, non-randomised, first-in-human trial", Lancet, 395, pp.1845~1854 (2020)
11. Logunov DY, "Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations : two open, non-randomised phase 1", 2 studies from Russia, 2020, pp.396, 887~897
12. Baden LR, "Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine", N Engl J Med, 384, pp.403~416 (2021)
13. Korea’s COVID-19 Vaccination Task Force Team, "COVID-19 vaccination guideline for health care workers", Korea’s COVID-19 Vaccination Task Force Team, ~ (2021)
14. "Immunization safety surveillance. Guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization" (2021)[URL]
15. Rodriguez-Coira J, "SARS-CoV-2 candidate vaccines-composition, mechanisms of action and stages of clinical development", Allergy, 76, pp.1922~1924 (2021)
16. Meyer M, "Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease", J Infect Dis, 217, pp.451~455 (2018)
17. Rauch S, "New vaccine technologies to combat outbreak situations", Front Immunol, 9, pp.1963~ (2018)
18. Choi MJ, "Use of ebola vaccine : recommendations of the Advisory Committee on Immunization Practices, United States, 2020", MMWR Recomm Rep, 70, pp.1~12 (2021)
19. Mathebula L, "Effects of vaccines in protecting against Ebola virus disease : protocol for a systematic review", BMJ Open, 9, pp.e029617~ (2019)
20. Bonhoeffer J, "Standardized case definitions of adverse events following immunization(AEFI)", Vaccine, 22, pp.547~550 (2004)
21. "Immunization safety surveillance. Guidelines for managers of immunization program managers on surveillance of adverse events following immunization" (2013)[URL]
22. "Immunization safety surveillance: guidelines for immunization program managers on surveillance of adverse events following immunization" (2021)[URL]
23. "COVID-19 vaccines: safety surveillance manual" (2021)[URL]
24. "Priority list of adverse events of special interest: COVID-19" (2021)[URL]
25. Korea Centers for Disease Control and Prevention, "Guidelines for management on surveillance of adverse events following immunization", Korea Centers for Disease Control and Prevention, ~ (2020)
26. Moylett EH, "Mechanistic actions of the risks and adverse events associated with vaccine administration", J Allergy Clin Immunol, 114, pp.1010~1020 (2004)
27. Hervé C, "The how’s and what’s of vaccine reactogenicity", NPJ Vaccines, 4, pp.39~ (2019)
28. "Assessment Report – Comirnaty (Pfizer/BioNTech)" (2021)[URL]
29. "Assessment Report – COVID-19 Vaccine AstraZeneca" (2021)[URL]
30. "Assessment Report – COVID-19 Vaccine Moderna" (2021)[URL]
31. Song Joon Young, "Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers", Journal of Korean Medical Science, 36(15), pp.1~4 (2021), 대한의학회[DOI]
32. Kim Si-Ho, "Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience", Journal of Korean Medical Science, 36(14), pp.1~8 (2021), 대한의학회[DOI]
33. Immunization guideline: 2018 report of the Committee on Infectious Diseases, "The Korean Pediatric Society", The Korean Pediatric Society, ~ (2018)
34. Haber P, "Vaccines and Guillain-Barré syndrome", Drug Saf, 32, pp.309~323 (2009)
35. Korea Centers for Disease Control and Prevention, "A study on the Guil lain-Barre syndrome to detect abnormal reaction after influenza vaccination", Korea Centers for Disease Control and Prevention, ~ (2017)
36. Lee H, "Incidence of Guillain-Barre syndrome is not associated with influenza vaccination in the elderly", Vaccines(Basel), 8, pp.431~ (2020)
37. Siegrist CA, "Mechanisms underlying adverse reactions to vaccines", J Comp Pathol, 137(Suppl 1), pp.S46~S50 (2007)
38. Miller E, "Idiopathic thrombocytopenic purpura and MMR vaccine", Arch Dis Child, 84, pp.227~229 (2001)
39. Schultz NH, "Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination", N Engl J Med, 384, pp.2124~2130 (2021)
40. Greinacher A, "Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination", N Engl J Med, 384, pp.2092~2101 (2021)
41. See I, "US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021", JAMA, 325, pp.2448~2456 (2021)
42. Oldenburg J, "Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination : guidance statement from the GTH", Hamostaseologie, 41, pp.184~189 (2021)
43. "Updated GTH statement on vaccination with the AstraZeneca COVID-19 vaccine" (2021)[URL]
44. "COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low platelets" (2021)[URL]
45. "COVID-19 vaccine safety update. AstraZeneca: Statement Issued on March 30th" (2021)[URL]
46. "MHRA issues new advice, concluding a possible link between COVID-19 vaccine AstraZeneca and extremely rare, unlikely to occur blood clots" (2021)[URL]
47. "Cases of cerebral venous sinus thrombosis with thrombocytopenia after receipt of the Johnson & Johnson COVID-19 vaccine. Health Alert Network (HAN)" (2021)[URL]
48. MacNeil JR, "Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen(Johnson & Johnson)COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients-United States, April 2021", MMWR Morb Mortal Wkly Rep, 70, pp.651~656 (2021)
49. "JCVI statement on use of the AstraZeneca COVID-19 vaccine" (2021)[URL]
50. "Some withheld vaccine Astra Zeneca vaccination starting again tomorrow (April 12)" (2021)[URL]
51. Wood RA, "An algorithm for treatment of patients with hypersensitivity reactions after vaccines", Pediatrics, 122, pp.e771~e777 (2008)
52. Fritsche PJ, "Vaccine hypersensitivity : update and overview", Swiss Med Wkly, 140, pp.238~246 (2010)
53. O’Brien TC, "Quantitation of residual host protein in chicken embryo-derived vaccines by radial immunodiffusion", Appl Microbiol, 21, pp.780~782 (1971)
54. American Academy of Pediatrics: Red Book 2015: report of the Committee on Infectious Diseases, , American Academy of Pediatrics, ~ (2015)
55. James JM, "Safe administration of the measles vaccine to children allergic to eggs", N Engl J Med, 332, pp.1262~1266 (1995)
56. Kelso JM, "Administering influenza vaccine to egg-allergic persons", Expert Rev Vaccines, 13, pp.1049~1057 (2014)
57. McKinney KK, "Ovalbumin content of 2010-2011 influenza vaccines", J Allergy Clin Immunol, 127, pp.1629~1632 (2011)
58. 노의정, "국내 유통되는 인플루엔자 백신에서 ELISA에 의한 계란 단백의 정량적 비교", Allergy Asthma & Respiratory Disease, 19(4), pp.345~353 (2009), 대한 소아알레르기 호흡기학회
59. Turner PJ, "SNIFFLE-2 Study Investigators. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study", BMJ, 351, pp.h6291~ (2015)
60. Turner PJ, "SNIFFLE Study Investigators. Safety of live attenuated influenza vaccine in atopic children with egg allergy", J Allergy Clin Immunol, 136, pp.376~381 (2015)
61. Committee on Infectious Diseases, "Recommendations for Prevention and Control of Influenza in Children, 2016-2017", Pediatrics, 138, pp.e20162527~ (2016)
62. Kelso JM, "Middleton’s allergy, principles and practice", pp.1371~1390 (2020), Elsevier
63. Smith D, "Ovalbumin content in the yellow fever vaccine", J Allergy Clin Immunol Pract, 3, pp.794~795 (2015)
64. Badiu I, "Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80", BMJ Case Rep, 2012, pp.bcr0220125~ (2012)
65. Shimabukuro T, "Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine", JAMA, 325, pp.780~781 (2021)
66. Eui jeong Roh, "Vaccine-related Anaphylaxis Cases Confirmed by KCDC from 2001–2016", Journal of Korean Medical Science, 35(38), pp.1~7 (2020), 대한의학회[DOI]
67. Stone CA Jr, "Immediate hypersensitivity to polyethylene glycols and polysorbates : more common than we have recognized", J Allergy Clin Immunol Pract, 7, pp.1533~1540 (2019)
68. Sellaturay P, "Polyethylene glycol-induced systemic allergic reactions(anaphylaxis)", J Allergy Clin Immunol Pract, 9, pp.670~675 (2021)
69. 김태세, "Polyethylene glycol에 의한 아나필락시스 1예", Allergy Asthma & Respiratory Disease, 6(5), pp.274~276 (2018), 대한 소아알레르기 호흡기학회
70. 이소희, "Anaphylaxis to Polyethylene Glycol (Colyte®) in a Patient with Diverticulitis", Journal of Korean Medical Science, 31(10), pp.1662~1663 (2016), 대한의학회
71. 이승은, "폴리에틸렌글리콜 3350에 의한 즉시형 과민반응 1예", Allergy Asthma & Respiratory Disease, 3(4), pp.307~309 (2015), 대한 소아알레르기 호흡기학회[DOI]
72. Sun Hee Lee, "Anaphylactic Shock Caused by Ingestion of Polyethylene Glycol", Intestinal research, 13(1), pp.90~94 (2015), 대한장연구학회[DOI]
73. Banerji A, "mRNA vaccines to prevent COVID-19 disease and reported allergic reactions : current evidence and suggested approach", J Allergy Clin Immunol Pract, 9, pp.1423~1437 (2021)
74. "Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States - Appendix B" (2021)[URL]
75. Zhou ZH, "Anti-PEG IgE in anaphylaxis associated with polyethylene glycol", J Allergy Clin Immunol Pract, 9, pp.1731~1733 (2021)
76. Hamad I, "Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process", Mol Immunol, 46, pp.225~232 (2008)
77. Wenande E, "Immediate-type hypersensitivity to polyethylene glycols : a review", Clin Exp Allergy, 46, pp.907~922 (2016)
78. Chung EH, "Vaccine allergies", Clin Exp Vaccine Res, 3, pp.50~57 (2014)
79. "Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States" (2021)[URL]

관련 논문AI추천